MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
and sales of...
$172,077K
Net cash provided by
investing activities
$133,933K
Canceled cashflow
$38,144K
Net change in cash
and cash...
$18,361K
Canceled cashflow
$115,572K
Purchases of marketable
securities
$38,056K
Purchases of property and
equipment
$88K
Stock-based compensation
expense
$9,852K
Accrued expenses and
other liabilities
$3,301K
Prepaid expenses and
other current assets
-$1,362K
Noncash interest
expense
$1,288K
Change in fair value of
embedded derivatives
-$460K
Amortization of right-of-use
asset
$126K
Depreciation
$58K
Other long-term
assets
-$40K
Proceeds from exercise of
stock options
$39K
Net cash used in
operating activities
-$115,538K
Net cash (used in)
provided by financing...
-$34K
Canceled cashflow
$16,487K
Canceled cashflow
$39K
Net loss
-$121,335K
Repurchase of common shares
to pay employee...
$73K
Accounts payable
-$5,094K
Accrued clinical trial
expenses
-$4,728K
Amortization of premiums and
accretion of discounts on...
$809K
Realized gain on
marketable securities
$59K
Back
Back
Cash Flow
source: myfinsight.com
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)